STOCK TITAN

Charles River Laboratories International (CRL) 10-K Filings

CRL NYSE

Here are the 10-K annual reports from Charles River Laboratories International, Inc. (CRL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow CRL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CRL filings page.

Rhea-AI Summary

Charles River Laboratories International, Inc. outlines its 2025 results and strategy as a global non‑clinical drug development partner. The company generated $4.0 billion in revenue, with Discovery and Safety Assessment contributing 59.8%, Research Models and Services 21.1%, and Manufacturing Solutions 19.1%.

The business spans over 120 sites in more than 20 countries and serves large pharma, biotech, academia, and government clients, with no single client above 4% of total revenue. Charles River is optimizing its footprint by planning to close or consolidate about 12 sites and divest non‑core assets representing roughly 7% of 2025 revenue.

The company ended 2025 with backlogs of approximately $1.9 billion in Discovery and Safety Assessment, $640 million in Research Models and Services, and $123 million in Manufacturing. It employed about 19,700 people and emphasizes animal welfare, new approach methodologies, and digital tools to support clients’ drug discovery and development.